Insmed Incorporated (INSM) Stake Raised by Alps Advisors Inc.
Alps Advisors Inc. increased its position in shares of Insmed Incorporated (NASDAQ:INSM) by 30.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 178,161 shares of the biopharmaceutical company’s stock after acquiring an additional 41,828 shares during the quarter. Alps Advisors Inc. owned 0.23% of Insmed worth $2,337,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System raised its holdings in shares of Insmed by 2.2% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 39,292 shares of the biopharmaceutical company’s stock valued at $516,000 after acquiring an additional 842 shares during the period. AQR Capital Management LLC raised its holdings in shares of Insmed by 4.4% during the third quarter. AQR Capital Management LLC now owns 103,376 shares of the biopharmaceutical company’s stock valued at $2,090,000 after acquiring an additional 4,373 shares during the period. Pacer Advisors Inc. acquired a new stake in shares of Insmed during the third quarter valued at approximately $155,000. Virtu Financial LLC acquired a new stake in shares of Insmed during the fourth quarter valued at approximately $183,000. Finally, MetLife Investment Advisors LLC raised its holdings in shares of Insmed by 40.2% during the third quarter. MetLife Investment Advisors LLC now owns 52,803 shares of the biopharmaceutical company’s stock valued at $1,068,000 after acquiring an additional 15,151 shares during the period.
Insmed stock opened at $24.90 on Friday. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -8.62 and a beta of 2.91. The company has a current ratio of 10.06, a quick ratio of 10.06 and a debt-to-equity ratio of 1.07. Insmed Incorporated has a twelve month low of $11.31 and a twelve month high of $31.58.
In other Insmed news, Director Alfred Altomari sold 5,500 shares of the company’s stock in a transaction that occurred on Thursday, January 10th. The shares were sold at an average price of $22.50, for a total value of $123,750.00. Following the transaction, the director now owns 42,442 shares in the company, valued at approximately $954,945. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Melvin Md Sharoky acquired 8,795 shares of the company’s stock in a transaction on Monday, November 12th. The stock was bought at an average price of $15.59 per share, for a total transaction of $137,114.05. Following the purchase, the director now owns 231,794 shares in the company, valued at approximately $3,613,668.46. The disclosure for this purchase can be found here. 3.88% of the stock is currently owned by corporate insiders.
Insmed Company Profile
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.
See Also: Index Funds
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.